4-(3-methanesulfonylphenyl)-1-propylpiperidine hydrobromide | 1440284-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3-methanesulfonylphenyl)-1-propylpiperidine hydrobromide
• 英文别名: Pridopidine HBr；4-(3-Methylsulfonylphenyl)-1-propylpiperidine;hydrobromide
• CAS: 1440284-30-9
• 化学式: BrH*C₁₅H₂₃NO₂S
• 分子量: 362.331
• InChiKey: SEKDGVOZMSJNLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.26
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[3-(甲基磺酰基)苯基]-1-丙基哌啶 在 氢溴酸 作用下， 以 乙醇 为溶剂， 反应 2.5h， 生成 4-(3-methanesulfonylphenyl)-1-propylpiperidine hydrobromide
  参考文献：
  名称：

  US2013/150406

  摘要：

  公开号：

文献信息

• THE HYDROBROMIDE SALT OF PRIDOPIDINE
  申请人：IVAX International GmbH

  公开号：EP2787997A1

  公开（公告）日：2014-10-15
• HYDROBROMIDE SALT OF PRIDOPIDINE
  申请人：Ivax International GmbH

  公开号：US20130150406A1

  公开（公告）日：2013-06-13

  This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.
• US9012476B2
  申请人：——

  公开号：US9012476B2

  公开（公告）日：2015-04-21
• US9814706B2
  申请人：——

  公开号：US9814706B2

  公开（公告）日：2017-11-14
• [EN] THE HYDROBROMIDE SALT OF PRIDOPIDINE<br/>[FR] BROMHYDRATE DE PRIDOPIDINE
  申请人：IVAX INT GMBH

  公开号：WO2013086425A1

  公开（公告）日：2013-06-13

  A salt of Pridopidine, a drug substance treats of Huntington's disease, include pharmaceutically acceptable hydfobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance. The salt compounds improve symptoms of psychosis, including schizo-phrenia and schizophreniform disorders as well as drug induced psychotic disorders, behavioral disorders usually first diagnosed in infancy, childhood, or adolescence as well as in impulse control disorders, and speech disorders such as stuttering may improve. Other psychotic disorders not characterized as schizophrenia, schizo affective syndromes as well as psychotic symptoms, delusions and hallucinations induced by other drugs may also improve. Disruptive behavior disorders such as attention deficit hyperactivity disorder (ADHD), conduct disorder and oppositional defiant disorder may also improve, and tic disorders such as Gilles de la Tourette' s syndrome. Salt compounds may be used for treating substance abuse disorders as well as disorders characterized by misuse of food.